BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31862729)

  • 1. Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma.
    Yin X; Bi R; Ma P; Zhang S; Zhang Y; Sun Y; Zhang Y; Jing Y; Yu M; Wang W; Tan L; Di W; Zhuang G; Cai MC
    J Med Genet; 2020 Sep; 57(9):605-609. PubMed ID: 31862729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
    Long X; Lu H; Cai MC; Zang J; Zhang Z; Wu J; Liu X; Cheng L; Cheng J; Cheung LWT; Shen Z; Zhou Y; Di W; Zhuang G; Yin X
    Br J Cancer; 2023 Jun; 128(11):2054-2062. PubMed ID: 36997661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular changes in endometriosis-associated ovarian clear cell carcinoma.
    Worley MJ; Liu S; Hua Y; Kwok JS; Samuel A; Hou L; Shoni M; Lu S; Sandberg EM; Keryan A; Wu D; Ng SK; Kuo WP; Parra-Herran CE; Tsui SK; Welch W; Crum C; Berkowitz RS; Ng SW
    Eur J Cancer; 2015 Sep; 51(13):1831-42. PubMed ID: 26059197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
    Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
    Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
    Yamaguchi K; Mandai M; Oura T; Matsumura N; Hamanishi J; Baba T; Matsui S; Murphy SK; Konishi I
    Oncogene; 2010 Mar; 29(12):1741-52. PubMed ID: 20062075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
    Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.
    Shin HY; Yang W; Chay DB; Lee EJ; Chung JY; Kim HS; Kim JH
    Mol Oncol; 2021 Apr; 15(4):987-1004. PubMed ID: 33331115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
    Xia Y; Ye S; Yang Y; Liu Y; Tong G
    Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
    [No Abstract]   [Full Text] [Related]  

  • 12. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
    Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
    Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
    Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
    Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis.
    Su KM; Lin TW; Liu LC; Yang YP; Wang ML; Tsai PH; Wang PH; Yu MH; Chang CM; Chang CC
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
    Vural S; Simon R; Krushkal J
    Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.
    Cunningham JM; Winham SJ; Wang C; Weiglt B; Fu Z; Armasu SM; McCauley BM; Brand AH; Chiew YE; Elishaev E; Gourley C; Kennedy CJ; Laslavic A; Lester J; Piskorz A; Sekowska M; Brenton JD; Churchman M; DeFazio A; Drapkin R; Elias KM; Huntsman DG; Karlan BY; Köbel M; Konner J; Lawrenson K; Papaemmanuil E; Bolton KL; Modugno F; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):132-141. PubMed ID: 34697060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
    Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
    Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
    EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.